BRPI0913724A2 - "formas farmacêuticas compreendendo poli (e-caprolactona)" - Google Patents
"formas farmacêuticas compreendendo poli (e-caprolactona)"Info
- Publication number
- BRPI0913724A2 BRPI0913724A2 BRPI0913724A BRPI0913724A BRPI0913724A2 BR PI0913724 A2 BRPI0913724 A2 BR PI0913724A2 BR PI0913724 A BRPI0913724 A BR PI0913724A BR PI0913724 A BRPI0913724 A BR PI0913724A BR PI0913724 A2 BRPI0913724 A2 BR PI0913724A2
- Authority
- BR
- Brazil
- Prior art keywords
- caprolactone
- poly
- dosage forms
- dosage
- forms
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9808908P | 2008-09-18 | 2008-09-18 | |
| US61/098,089 | 2008-09-18 | ||
| US22349709P | 2009-07-07 | 2009-07-07 | |
| US61/223,497 | 2009-07-07 | ||
| PCT/IB2009/006917 WO2010032128A1 (en) | 2008-09-18 | 2009-09-17 | Pharmaceutical dosage forms comprising poly(e-caprolactone) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0913724A2 true BRPI0913724A2 (pt) | 2017-06-20 |
| BRPI0913724B1 BRPI0913724B1 (pt) | 2020-03-10 |
| BRPI0913724B8 BRPI0913724B8 (pt) | 2021-05-25 |
Family
ID=41435149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0913724A BRPI0913724B8 (pt) | 2008-09-18 | 2009-09-17 | formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110165248A1 (pt) |
| EP (1) | EP2344136B1 (pt) |
| JP (1) | JP5539991B2 (pt) |
| KR (1) | KR101456741B1 (pt) |
| CN (1) | CN102159193B (pt) |
| AU (1) | AU2009294308B2 (pt) |
| BR (1) | BRPI0913724B8 (pt) |
| CA (1) | CA2737257C (pt) |
| CO (1) | CO6361903A2 (pt) |
| ES (1) | ES2586439T3 (pt) |
| IL (1) | IL211314A (pt) |
| MX (1) | MX342643B (pt) |
| NZ (2) | NZ601200A (pt) |
| RU (1) | RU2523896C2 (pt) |
| WO (1) | WO2010032128A1 (pt) |
| ZA (1) | ZA201101948B (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
| WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
| CA2611081C (en) * | 2005-06-03 | 2016-05-31 | Egalet A/S | A drug delivery system for delivering active substances dispersed in a dispersion medium |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| WO2009114648A1 (en) | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| JP5827123B2 (ja) * | 2008-09-16 | 2015-12-02 | ウェルズ ファーゴ バンク ナショナル アソシエイション | 乱用の可能性が低いｐｅｇ化オピオイド |
| WO2010088911A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Pharmaceutical compositions resistant to abuse |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| PH12012502083A1 (en) | 2010-05-10 | 2017-07-26 | Euro Celtique Sa | Manufacturing of active-free granules and tablets comprising the same |
| EP2568965A1 (en) | 2010-05-10 | 2013-03-20 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
| US9700508B2 (en) | 2010-05-10 | 2017-07-11 | Euro-Celtique S.A. | Pharmaceutical compositions comprising hydromorphone and naloxone |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| EA201490500A1 (ru) | 2011-08-30 | 2014-06-30 | Университейт Гент | Многослойный высвобождающий состав |
| CN104010630A (zh) * | 2011-12-09 | 2014-08-27 | 普渡制药公司 | 包含聚(ε-己内酯)和聚氧乙烯的药物剂型 |
| US9993422B2 (en) | 2012-04-18 | 2018-06-12 | SpecGx LLC | Immediate release, abuse deterrent pharmaceutical compositions |
| BR112015000150A2 (pt) | 2012-07-06 | 2017-06-27 | Egalet Ltd | composições farmacêuticas dissuasoras de abuso de liberação controlada |
| CA2901802C (en) | 2013-03-15 | 2021-03-02 | Mallinckrodt Llc | Abuse deterrent solid dosage form for immediate release with functional score |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015071380A1 (en) | 2013-11-13 | 2015-05-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2016004170A1 (en) | 2014-07-03 | 2016-01-07 | Mallinckrodt Llc | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US10172945B2 (en) * | 2015-02-04 | 2019-01-08 | National Health Research Institutes | Sorbitan polyester conjugates for stabilizing water-in-oil emulsions and delivering controlled release of bioactive agents |
| EP3181124A1 (en) * | 2015-12-16 | 2017-06-21 | Universität Basel | Abuse deterrent pharmaceutical dosage forms |
| EP3727384A4 (en) | 2017-12-20 | 2021-11-03 | Purdue Pharma L.P. | ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES |
| EP3856160A4 (en) | 2018-09-25 | 2022-07-06 | SpecGx LLC | ABUSE-PROOF IMMEDIATE RELEASE CAPSULE DOSAGE FORMS |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4148871A (en) * | 1977-10-11 | 1979-04-10 | Pitt Colin G | Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers |
| FR2557459B1 (fr) * | 1984-01-02 | 1986-05-30 | Lhd Lab Hygiene Dietetique | Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice |
| US5716565A (en) * | 1993-09-27 | 1998-02-10 | Alfred University | Process for making ultra-fine stabilized zirconia particles |
| EP0804249A2 (en) * | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| DE69734060T2 (de) * | 1996-05-24 | 2006-06-29 | Angiotech Pharmaceuticals, Inc., Vancouver | Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| ATE303795T1 (de) * | 1998-12-16 | 2005-09-15 | Aventis Pharma Inc | In biologisch abbaubare polymere eingekapselter serotoninrezeptor-antagonist und deren herstellungsverfahren |
| RS20050812A (sr) * | 2003-04-30 | 2007-12-31 | Purdue Pharma L.P., | Transdermalni dozni oblik otporan na promene |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
| US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| MXPA06003392A (es) * | 2003-09-25 | 2006-06-08 | Euro Celtique Sa | Combinacion farmaceutica de hidrocodona y naltrexona. |
| TW201509943A (zh) * | 2004-03-30 | 2015-03-16 | Euro Celtique Sa | 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 |
| WO2006002365A2 (en) * | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
| SK286087B6 (sk) * | 2004-08-18 | 2008-03-05 | Zentiva, A. S. | Spôsob prípravy oxykodonu |
| CA2598204C (en) * | 2004-11-09 | 2015-01-13 | Board Of Regents, The University Of Texas System | Stabilized hme composition with small drug particles |
| CA2594373A1 (en) * | 2005-01-28 | 2006-08-03 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
| US20080193543A1 (en) * | 2005-05-17 | 2008-08-14 | Brown University Research Foundation | Drug Delivery Formulations For Targeted Delivery |
| ATE476997T1 (de) * | 2005-07-05 | 2010-08-15 | Abbott Gmbh & Co Kg | Zusammensetzung und dosierform mit einer festen oder halbfesten matrix |
| FR2901478B1 (fr) * | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| WO2008027442A2 (en) * | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
| NZ577560A (en) * | 2007-01-16 | 2012-01-12 | Egalet Ltd | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
-
2009
- 2009-09-17 BR BRPI0913724A patent/BRPI0913724B8/pt not_active IP Right Cessation
- 2009-09-17 RU RU2011121010/15A patent/RU2523896C2/ru not_active IP Right Cessation
- 2009-09-17 KR KR1020117008610A patent/KR101456741B1/ko active Active
- 2009-09-17 CA CA2737257A patent/CA2737257C/en active Active
- 2009-09-17 MX MX2011002966A patent/MX342643B/es active IP Right Grant
- 2009-09-17 NZ NZ601200A patent/NZ601200A/en not_active IP Right Cessation
- 2009-09-17 AU AU2009294308A patent/AU2009294308B2/en active Active
- 2009-09-17 CN CN200980136742.4A patent/CN102159193B/zh active Active
- 2009-09-17 ES ES09786269.2T patent/ES2586439T3/es active Active
- 2009-09-17 US US13/055,535 patent/US20110165248A1/en not_active Abandoned
- 2009-09-17 JP JP2011527420A patent/JP5539991B2/ja active Active
- 2009-09-17 NZ NZ592276A patent/NZ592276A/xx not_active IP Right Cessation
- 2009-09-17 EP EP09786269.2A patent/EP2344136B1/en active Active
- 2009-09-17 WO PCT/IB2009/006917 patent/WO2010032128A1/en not_active Ceased
-
2011
- 2011-02-20 IL IL211314A patent/IL211314A/en active IP Right Grant
- 2011-03-15 ZA ZA2011/01948A patent/ZA201101948B/en unknown
- 2011-04-13 CO CO11045846A patent/CO6361903A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20110165248A1 (en) | 2011-07-07 |
| BRPI0913724B8 (pt) | 2021-05-25 |
| CN102159193A (zh) | 2011-08-17 |
| JP5539991B2 (ja) | 2014-07-02 |
| IL211314A0 (en) | 2011-04-28 |
| EP2344136B1 (en) | 2016-06-15 |
| KR20110055734A (ko) | 2011-05-25 |
| ZA201101948B (en) | 2011-11-30 |
| IL211314A (en) | 2016-03-31 |
| JP2012502968A (ja) | 2012-02-02 |
| BRPI0913724B1 (pt) | 2020-03-10 |
| CA2737257A1 (en) | 2010-03-25 |
| AU2009294308A1 (en) | 2010-03-25 |
| RU2011121010A (ru) | 2012-11-27 |
| NZ592276A (en) | 2012-12-21 |
| MX2011002966A (es) | 2011-09-26 |
| CN102159193B (zh) | 2015-09-16 |
| MX342643B (es) | 2016-10-07 |
| CA2737257C (en) | 2016-11-15 |
| WO2010032128A1 (en) | 2010-03-25 |
| ES2586439T3 (es) | 2016-10-14 |
| CO6361903A2 (es) | 2012-01-20 |
| KR101456741B1 (ko) | 2014-10-31 |
| EP2344136A1 (en) | 2011-07-20 |
| RU2523896C2 (ru) | 2014-07-27 |
| NZ601200A (en) | 2014-02-28 |
| AU2009294308B2 (en) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0913724A2 (pt) | "formas farmacêuticas compreendendo poli (e-caprolactona)" | |
| BRPI0714539A2 (pt) | "formas farmacêuticas" | |
| DK2175851T3 (da) | Biofilmbehandling | |
| SMT201500328B (it) | Trattamento di leucemia linfoblastica acuta | |
| DK1907037T3 (da) | Medikamentdispenser. | |
| DK1986650T3 (da) | Manipulationssikre doserignsformer | |
| DK2364742T4 (da) | Anordning til afgivelse af lægemiddel | |
| EP2213436A4 (en) | CLAMPING DEVICE | |
| CR20130381A (es) | Formas farmacéuticas con propiedades farmacocinéticas mejoradas | |
| BRPI0812354A2 (pt) | Composição farmacêutica não-aquosa. | |
| BRPI0817430A2 (pt) | Fluoroalquenil poli [1,6] glicosídeos | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| DE602007011183D1 (de) | Hydrazinfunktionalisiertes Polymer | |
| DK2173831T3 (da) | Brøndbehandling | |
| DE502007003750D1 (de) | Klemmvorrichtung | |
| EP2197448A4 (en) | dosing schedule | |
| DK1928427T3 (da) | Hidtil ukendt dosisformulering | |
| DK2131818T3 (da) | Ny doseringsform | |
| EP2184303A4 (en) | Copolymer | |
| DK2193283T3 (da) | Låseanordning | |
| DE602006013740D1 (de) | Verriegelungsvorrichtung | |
| DK2053010T3 (da) | Låseindretning | |
| DE502006000713D1 (de) | Verriegelungsvorrichtung | |
| DK1928464T3 (da) | Ny parenteral carbamazepin-formulering | |
| DK2001499T3 (da) | Anvendelse af TGS-6 til behandling af osteoporose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2688 DE 12-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |